Phaseline

Companies › Newleos Therapeutics

Newleos Therapeutics: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 1 Phase 1, 1 Phase 2; Psychiatry; next expected readout Jan 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
NTX-1472
V1a receptor antagonist
AVPR1APhase 2Social Anxiety Disorder (SAD)Jan 2027
NTX-2001
TAAR1 receptor partial agonist
TAAR1Phase 1Alcohol Use DisorderMar 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07323784NTX-1472Phase 2Social Anxiety Disorder (SAD)PsychiatryJan 2027
NCT07520292NTX-2001Phase 1Alcohol Use DisorderPsychiatryMar 2027

From the company's SEC filings

Private offerings reported to the SEC (Form D)

Targets

TAAR1 (1) AVPR1A (1)

Companies with the same targets

Otsuka Minerva Neurosciences PharmaIN Tiohundra

Companies built like this

Draig Therapeutics Kadence Bio HB BioTech Beckley Psytech Synendos Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.